Moving Beyond Directly Observed Therapy for Tuberculosis

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
² Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, New York, United States of America.
³ Massachusetts General Hospital, Harvard Medical School, Harvard School of Public Health, Boston, Massachusetts, United States of America; Mbarara University of Science and Technology, Mbarara, Uganda.

John Z Metcalfe et al. PLoS Med. 2015.

. 2015 Sep 15;12(9):e1001877.

doi: 10.1371/journal.pmed.1001877. eCollection 2015 Sep.

¹ Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
² Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, New York, United States of America.
³ Massachusetts General Hospital, Harvard Medical School, Harvard School of Public Health, Boston, Massachusetts, United States of America; Mbarara University of Science and Technology, Mbarara, Uganda.

No abstract available

Conflict of interest statement

The authors have declared that no competing interests exist.

1. Selkon JB, Devadatta S, Kulkarni KG, Mitchison DA, Narayana AS, Nair CN, et al. The Emergence of Isoniazid-Resistant Cultures in Patients with Pulmonary Tuberculosis during Treatment with Isoniazid Alone or Isoniazid Plus Pas. Bull World Health Organ. 1964;31:273–94. - PMC - PubMed
1. Yeager RL, Munroe WG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. American review of tuberculosis. 1952;65(5):523–46. - PubMed
1. Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. N Engl J Med. 1970;283(12):616–21. - PubMed
1. Lee M, Cho SN, Barry CE 3rd, Song T, Kim Y, Jeong I. Linezolid for XDR-TB—Final Study Outcomes. N Engl J Med. 2015;373(3):290–1. 10.1056/NEJMc1500286 - DOI - PMC - PubMed
1. Chaisson RE, Coberly JS, De Cock KM. DOTS and drug resistance: a silver lining to a darkening cloud. Int J Tuberc Lung Dis. 1999;3(1):1–3. - PubMed